Effect of semaphorin 3A expression on clinicopathological features and prognosis in oropharyngeal carcinoma

Abstract

Semaphorin 3A (SEMA3A) is a well-known axon guidance molecule in the nervous system. It is also known as a tumor suppressor in various cancers. In the present study, we examined the relationships between SEMA3A and clinicopathologic features and neoangiogenesis and its prognostic significance for oropharyngeal cancer (OPC) patients. Thirty-two OPC patients who underwent biopsy and 17 normal patients who underwent tonsillectomy were analyzed for SEMA3A expression by immunohistochemical analysis. We also analyzed 22 OPC specimens for CD34 expression as a marker of neoangiogenesis. SEMA3A was significantly downregulated in OPC compared with normal tonsil tissues (p = 0.005). SEMA3A expression was negatively correlated with CD34 expression, which suggested that a higher microvascular density corresponded to a lower expression of SEMA3A (r = -0.466, p = 0.033). Moreover, the higher SEMA3A expression cohort showed better survival than the lower SEMA3A expression cohort regardless of human papillomavirus (HPV) status (p = 0.035). These results suggest that SEMA3A expression is a prognostic marker for survival and is associated with antiangiogenesis in OPC.